This presentation contains certain forward-looking statements about Minerva Neurosciences that are intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation

Innovation to change the way we treat

CNS disease February / March 2017 Nasdaq: NERV Exhibit 99.1

This presentation contains certain

forward-looking statements about Minerva Neurosciences that are intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking

statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended

to identify forward-looking statements. These statements include, but are not limited to: the benefits, efficacy and safety of our new formulations; whether studies performed on analogs or backups of our compounds are a good predictor of the

clinical efficacy of our compounds; the timing and results of future clinical milestones; the timing of future clinical trials and results of such clinical trials; statements regarding our ability to successfully develop and commercialize our

therapeutic products; our ability to expand our long-term business opportunities; our expectations regarding approval for our products by the U.S. Food and Drug Administration or equivalent foreign regulatory agencies; estimates regarding the market

potential for our products; financial projections and estimates and their underlying assumptions; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally

beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, but are not limited to: the benefits,

efficacy and safety of our new formulations; whether analogs or backups of our compounds are a good predictor of the clinical efficacy of our compounds; the timing and results of future clinical milestones; the timing of future clinical trials and

results of such clinical trials; whether any of our therapeutic candidates will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent

foreign regulatory agencies and for which indications; whether any of our therapeutic candidates will be successfully marketed if approved; whether our therapeutic product discovery and development efforts will be successful; our ability to achieve

the results contemplated by our collaboration agreements; the strength and enforceability of our intellectual property rights; competition from pharmaceutical and biotechnology companies; the development of and our ability to take advantage of the

market for our therapeutic products; our ability to raise additional capital to fund our operations on terms acceptable to us; general economic conditions; and the other risk factors contained in our periodic and interim reports filed with the

Securities and Exchange Commission which are available on the SEC website at www.sec.gov. Our audience is cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any

obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events. All trademarks, trade names and service marks appearing in

this presentation are the property of their respective owners. Forward-Looking Statement Safe-Harbor

Investment highlights Late-stage

pipeline targets schizophrenia, major depressive disorder (MDD), insomnia and Parkinson's Our product candidates represent true innovation in disease treatment and management by addressing significant unmet needs of large patient populations

MIN-101 may change schizophrenia treatment paradigm FDA end-of-Phase 2 meeting early Q2 Initiation of Phase 3 in Q3 2017 >$91.9m million in cash 30 Sept 2016 Experienced clinical development team who have participated in more than 800 clinical

Our team Remy Luthringer, Ph.D.,

President and Chief Executive Officer Deep clinical development experience with > 150 CNS molecules Previous head of FORENAP Institute for Research in Neurosciences and Neuropsychiatry Extensive practice in clinical psychiatry, with Ph.D. in

neurosciences and clinical pharmacology Geoff Race, Executive Vice President, Chief Financial Officer and Chief Business Officer Senior executive with multiple clinical and development-stage biopharmaceutical companies Expertise in mergers,

acquisitions and licensing Track record in business development Michael Davidson, M.D., Chief Medical Officer Consultant to the biopharmaceutical industry, with insights into development strategy and regulatory review of CNS compounds

Internationally recognized author, researcher, award recipient and thought leader Professor of Psychiatry at Sackler School of Medicine, Tel Aviv University

True differentiation in our approach

Extensive knowledge of the pathology, course and impact of CNS diseases Focus on outcomes that address unmet needs (no "me-too" products) and on patient populations who will benefit from treatment with our compounds Understanding of the

impact of novel MOAs and the limitations of current treatments Expertise in CNS clinical trial design and conduct

Program Origin Primary Indications

Mechanisms of Action Pre- clinical Phase I Phase II Status Next Steps MIN-101 Mitsubishi Tanabe Schizophrenia 5-HT2A antagonist Sigma2 antagonist Results announced May & October 2016 End of Phase II meeting with FDA scheduled

early in Q2 2017 Initiation of pivotal Phase III trial planned in Q3 2017 MIN-202 Janssen (under co-development) Primary Insomnia Major Depressive Disorder Selective Orexin2 antagonist Results Announced January 2016 Results announced March

2016 Phase II trial preparation underway Next trials in insomnia disorder and MDD planned for second half of 2017 MIN-117 Mitsubishi Tanabe Major Depressive Disorder 5-HT1A 5HT transporter Alpha-1a, b Dopamine

transporter 5-HT2A antagonist Results announced May 2016 Planning underway for next phase of clinical trials expected to begin in late 2017 MIN-301 Mind-NRG Parkinson's Disease Neuregulin 1 1 activating ErbB4 Pre-clinical

activities ongoing Filing of IND or IMPD, with Phase I expected to initiate thereafter Phase IIb completed Phase IIa completed Phase Ib completed Pre-clinical Phase IIa completed Changing the way we treat CNS diseases

MIN-101 A new paradigm for the

treatment of schizophrenia

Schizophrenia: a devastating chronic

disease with a high burden for patients, families and society Affects ~30 million people worldwide1 Often starts in late teens or early adulthood2 75% patients are non-adherent to existing therapies within 2 years of being discharged from hospital3

Medication non-adherence is the single largest factor in relapse4 Schizophrenia: not a classic neurodegenerative disease yet associated with progressive atrophic changes 1. Global Prevalence of Schizophrenia PLOS Medicine, 2005 2. NIMH 3. Weiden PJ

et al. Psychiatr Serv,1995; 46:1049-1054 4. Weiden PJ (2004), Kozma C, Grogg A et al. Psychiatr Serv, 2004, 55:886-891

Severity of Illness Chronic Progression

of Negative Symptoms & Cognitive Impairment Youth 0-18 Adult 18-40 Mature >40 Cognitive Symptoms Negative Symptoms Positive Symptoms Schizophrenia is a dynamic chronic disease - prevalence of symptoms changes over the lifetime of the

The unmet needs in schizophrenia

Tranquilizers and antipsychotics treat Positive Symptoms delusions and hallucinations but not Cognition Negative Symptoms and have - debilitating side effects caused by blocking D2 3. Negative Symptoms - apathy - restricted social interaction - poor

emotional feelings - physical and mental slowness - depressed mood 2. Impaired Cognition Brain of a patient with long-standing schizophrenia Normal brain Rate of Grey Matter Loss: None Moderate / low High Source: Business Insights, NIMH, DSM-5,

Journal of Clinical Psychiatry, PNAS,

Responding to unmet needs in

schizophrenia Lack of efficacy of current Rx on negative symptoms Substantial side effect burden Lack of efficacy of current Rx on cognitive decline In addition, positive symptom scores remained stable over ~9 months when patients were taking

MIN-101 Unmet need MIN-101 clinical benefits (Ph IIb) A direct (not pseudo-effect) on negative symptoms and an improvement in depression in schizophrenia MIN-101 showed cognitive improvement Absence of typical side effects associated with D2

MIN-101: a new approach and MOA A

unique dual MOA; 5-HT2A antagonist + Sigma2 antagonist No direct dopamine blocking, unlike most (or all) available antipsychotics Specific affinity for 2, 5-HT2A and 1-adrenergic receptors No affinity (>1000 nM) for other receptors

including dopaminergic, muscarinic, cholinergic and histaminergic receptors Behavioral pharmacology is consistent with an antagonistic effect for 2 and 5-HT2A receptors

MIN-101 Phase IIb study:

monotherapy, double-blind, placebo-controlled in schizophrenic patients with negative symptoms MIN-101 64mg (n = 83) Screening Treatment & Assessments 4 weeks Screening 12 week double-blind phase core study' 24 week

open-label extension' phase Placebo (n = 83) MIN-101 32mg (n = 78) R MIN-101 64mg MIN-101 32mg Crossover = Randomization R

MIN-101 Phase IIb data -

setting a new standard Treatment resulted in statistically significant improvement in PANSS negative symptoms and total PANSS scores Statistically superior to placebo on multiple key secondary endpoints Positive effects were specific for negative

symptoms and not secondary to improvement in other symptoms or side effects MIN-101 well tolerated, with incidence and types of side effects not differing significantly from placebo; no "atypical side-effects" observed (two patients

(2/162) receiving highest dose of MIN-101 discontinued based on QT prolongation)

p-value (MIN-101 vs placebo) Effect

size (MIN-101 vs placebo) Endpoint at 12 weeks 32mg 64mg 32mg 64mg Primary objective 5-Factor Negative Score (i.e., Negative Symptoms, Pentagonal Structure): 0.0240 0.0036 0.45 0.57 Secondary objectives PANSS total score 0.0819 0.0031 0.34 0.57

3-Factor Negative Score 0.0064 0.0004 0.54 0.70 3-Factor Positive Score 0.4018 0.3067 0.16 0.20 3-Factor General Psychopathology Score 0.2359 0.0034 0.23 0.56 5-Factor Positive Score 0.5045 0.2146 -0.13 0.24 5-Factor Dysphoric Mood Score 0.5644

0.0266 0.11 0.43 5-Factor Activation Score 0.0240 0.0118 0.44 0.49 5-Factor Autistic Preoccupation Score 0.6700 0.2408 0.08 0.22 CGI-S* (severity) 0.0982 0.0234 0.35 0.43 CGI-I** (improvement) 0.2378 0.0032 0.33 0.57 BNSS (Brief Negative Symptom

Scale) 0.0869 0.0040 0.33 0.56 BACS cognition assessment (Composite T-Score) 0.0595 0.6967 0.30 0.06 - Executive Function: Tower of London 0.3937 0.5995 0.16 -0.10 - Motor Function: Token Motor Test 0.0306 0.0493 0.42 0.38 - Motor Function: Symbol

Coding Task 0.6310 0.0781 -0.09 -0.33 - Total Verbal Fluency 0.0076 0.0554 0.51 0.36 - Verbal Memory & Learning: Verbal Memory 0.1544 0.3158 0.27 0.19 - Working Memory: Digit Sequence Task 0.0664 0.8826 0.36 0.03 Exploratory objectives CDSS

depression scale 0.1756 0.0091 0.25 0.46 PSP personal and social performance - Socially Useful Activities 0.4775 0.0601 0.14 0.38 - Personal & Social Relationships 0.9174 0.0129 0.02 0.53 - Self-care 0.1736 0.0210 0.27 0.46 - Disturbing &

Aggressive Behavior 0.0532 0.0057 0.36 0.51 Bold red text indicates p-value 0.05 * Analyzed using ranked data: change from Baseline and ES are based on observed change from baseline data ** Analyzed using ranked data; ES is based on observed

data Final results of MIN-101 Phase IIb efficacy analyses (12 weeks) Green text indicates moderate or large ES

Efficacy: Primary endpoint -

clinically meaningful effect on negative symptoms with rapid onset of effect and continuous improvement throughout the study at both doses Onset of effect observed after 2 weeks (measured at first visit) WEEK

Efficacy: Secondary endpoint (1)

Improvement in negative symptoms also observed with additional measurement scale PANSS Negative Symptom Score (3 Factors) - Change from Baseline (MMRM) (ITT Population) WEEK

Efficacy: Secondary endpoint (2)

Demonstrated improvement in Total PANSS driven by improvement in negative symptoms WEEK

Efficacy: Secondary endpoint (4)

PANSS positive symptoms score (3 Factors) indicates MIN-101 maintains stability in positive symptoms WEEK

Extension Phase Baseline for

patients who crossed from placebo to MIN-101 is start of open label (Week 12)

MIN-101C03: Negative Symptoms

(Pentagonal Structure) Continued improvement over 36 weeks in both doses Baseline for Placebo-to-MIN-101 is From Start of Open Label Core Phase Extension Phase Baseline for Placebo-to-MIN-101 is From Start of Open Label (Week 12)

MIN-101C03: Positive Symptoms

(3-Factors) Stable over 36 weeks in both doses Baseline for Placebo-to-MIN-101 is From Start of Open Label

MIN-202 (JNJ42847922) A drug to

treat insomnia & depressive disorders by restoring physiological sleep A co-development/co-commercialisation program with;

Insomnia affects about 10% of adults

and the majority of people with depression

MIN-202: Exploratory study in

patients with MDD and comorbid insomnia (n=20) indicate significant improvements in key sleep metrics

Phase IIa in primary insomnia:

achievement of primary endpoint of improvement in sleep efficiency complemented by increase in total sleep time 8.12 % p <0.001 5.77 % p <0.001 Sleep Efficiency = (Total Sleep Time/480) * 100% PSG recording = 480 min

MIN-117 Potential for a more

effective and safer treatment to address the unmet medical needs of Major Depressive Disorder patients

Unmet need in Major Depressive

Disorder: treatments with faster onset and better response, without side effects Treatments that: Act rapidly Are effective in patients who do not respond to or receive only partial benefit from existing medicines Do not impair cognition or sexual

function Free patients from debilitating side-effects Improve sleep What do we need? Major depression: primary cause of disability worldwide by 20301 ~6 million patients in US with treatment- resistant depression2 Only ~30% of patients achieve

remission using current treatments3 Current therapies have slow onset of effect; typically 4 - 8 weeks World Health Organization, "Global Burden of Mental Disorders," 2011 IMS and Truven Health Cleveland Clinic Journal of Medicine

Volume 75. Number 1 January 2008

MIN-117C01: Phase IIa study design

MIN-117 2.5mg (n = 21) Screening Treatment & Assessments 4 weeks Screening Day -28 to -1* 6 week double blind treatment phase 2 wk post treatment follow-up phase MIN-117 0.5mg (n = 21) R Paroxetine 20mg (n = 21) Placebo (n = 21) *Includes